Premature ejaculation: old story, new insights.

Abstract

Conventional theories and therapies for premature ejaculation (PE) are based on assumptions not always supported by evidence. This review of the current literature on the physiology of the ejaculatory control, pathogenesis of PE, and available therapies shows that PE is still far from being fully understood. However, several interesting hypotheses have been formulated, and solid, evidence-based clinical data are currently available for dapoxetine, the unique, first-line, officially approved pharmacotherapy for PE. Further growth in the field of PE will occur only when we shift from opinion-based classifications, definitions, and hypotheses to robust, noncontroversial data grounded on evidence.

• Authors: Emmanuele A Jannini, Giacomo Ciocca, Erika Limoncin, Daniele Mollaioli, Stefania Di Sante, Daniele Gianfrilli, Francesco Lombardo, Andrea Lenzi
• Journal: Fertility and sterility (Fertil Steril) Vol. 104 Issue 5 Pg. 1061-73 (Nov 2015) ISSN: 1556-5653 [Electronic] United States
• PMID: 26409323 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Chemical References

• Benzylamines
• Hormones
• Naphthalenes
• Serotonin Uptake Inhibitors
• Serotonin
• dapoxetine

Topics

• Animals
• Benzylamines (therapeutic use)
• Ejaculation (drug effects)
• Hormones (metabolism)
• Humans
• Infertility, Male (etiology, physiopathology)
• Male
• Marital Therapy
• Naphthalenes (therapeutic use)
• Penis (innervation)
• Premature Ejaculation (diagnosis, etiology, physiopathology, psychology, therapy)
• Recovery of Function
• Risk Factors
• Serotonin (metabolism)
• Selective Serotonin Reuptake Inhibitors (therapeutic use)
• Sexual Behavior
• Synaptic Transmission
• Treatment Outcome